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ABSTRACT 32 
 33 
The relationship between the Human Cytomegalovirus (HCMV) and tumors has been 34 
extensively investigated, mainly in glioblastoma multiforme (GBM), a malignant tumor 35 
of the central nervous system with low overall survival. Several reports demonstrated 36 
the presence of HCMV in GBM, although typically restricted to a low number of cells, 37 
and studies indicated that viral proteins have the ability to dysregulate cellular 38 
processes and increase tumor malignancy. Treatment of GBM involves the use of the 39 
chemotherapeutic agents Temozolomide (TMZ) and Carmustine (BCNU), which lead 40 
to attachment of adducts to the DNA backbone, causing errors during replication and 41 
consequent cell death. It is known that HCMV infection can modulate DNA repair 42 
pathways, but the effects the virus may exhibit during chemotherapy are unknown. 43 
Here we approach this question by analyzing HCMV infection and viral protein 44 
accumulation in GBM cell lines with different genotypes and their response to TMZ and 45 
BCNU in the presence of the virus. We demonstrate that A172, TP365MG and 46 
U251MG GBM cells are efficiently infected by both low passage (TB40E) and high 47 
passage (AD169) HCMV strains. However, the GBM cell lines vary widely in 48 
permissiveness to viral gene expression and exhibit very different patterns of 49 
immediate early, early and late protein accumulation. HCMV reduces viability of 50 
permissive GBM cells in a multiplicity-dependent manner both in the absence and 51 
presence of TMZ or BNCU. In sum, we demonstrate that GBM cell lines are equally 52 
susceptible but differentially permissive to infection by both low and high passage 53 
strains of HCMV. This observation not only indicates that viral replication is largely 54 
controlled by cellular factors in this system, but also provides a possible explanation 55 
for why viral gene products are found in only a subset of cells in GBM tumors. 56 
Furthermore, we conclude that the virus does not confer increased resistance to 57 
chemotherapeutic drugs in various GBM cell lines but instead reduces tumor cell 58 
viability. These results highlight that the oncomodulatory potential of HCMV is not 59 
limited to cancer promoting activities but also comprises adverse effects on tumor cell 60 
proliferation or survival. 61 
 62 
INTRODUCTION 63 
 64 
Human cytomegalovirus (HCMV) is a member of the herpesvirus family and is 65 
present in the majority of people worldwide, including almost 100% of the adult 66 
population in developing countries [1]. Congenital infection by HCMV is the most 67 
common cause of severe neurological impairments including hearing loss, optic 68 
atrophy and microcephaly in many parts of the world [1]. The virus is also a life-69 
threatening pathogen in immunocompromised individuals such as transplant recipients 70 
as well as patients with AIDS or cancer [2]. 71 
HCMV has been detected in many tumor types [3–12] , and the relationship 72 
between the virus and cancer has been investigated most extensively in glioblastoma 73 
multiforme (GBM) [13–16].  GBM is the most aggressive primary brain tumor with a 74 
median survival of 15 months and an unknown etiology [17]. GBM is characterized by 75 
the presence of a heterogeneous population of cells that are infiltrative, angiogenic and 76 
poorly metastatic [18]. Various reports demonstrated the presence of HCMV DNA, 77 
transcripts and/or proteins in GBM samples (reviewed in [16]).  In addition, a number 78 
of studies showed that viral proteins can modulate the phenotype of GBM cells leading 79 
to cell proliferation [19], cell immortalization [20], cell migration [21, 22], stem cell 80 
maintenance [23, 24], angiogenesis [22, 25–27] and immunomodulation [28]. Although 81 
HCMV is not considered to be oncogenic, it is believed that viral proteins may increase 82 
cellular malignancy and contribute to tumor progression, a phenotype called 83 
oncomodulation [29]. In fact, studies suggest that extracellular factors released during 84 
HCMV infection can cause immunosuppression of the tumor microenvironment 85 
(reviewed in [30] ), but the virus may also be more directly involved in the malignant 86 
phenotype of tumor cells (reviewed in [31]). 87 
The standard GBM treatment is surgical resection followed by radiotherapy and 88 
chemotherapy. The cytotoxic treatment with Temozolomide (TMZ) and Carmustine 89 
(bis-chloroethylnitrosourea, BCNU) inserts alkyl adducts into the DNA backbone, 90 
causing errors during DNA replication due the formation of numerous DNA double-91 
strand breaks (DSBs) not repaired by the cellular machinery. This lack in DNA repair 92 
ultimately leads to cell death [32]. Despite the standard treatment, less than 5% of 93 
GBM patients live longer than 5 years after diagnosis (reviewed in [33]), mainly 94 
because of the acquired and intrinsic drug resistance (reviewed in [34]). The main 95 
mechanism of chemotherapy resistance is mediated by O6-methylguanine DNA 96 
methyltransferase (MGMT), a suicide repair protein that removes DNA adducts formed 97 
at the O6-position of guanidine in response to alkylating agents, such as TMZ. MGMT 98 
expression is associated with poor patient response to alkylating therapies. Other 99 
molecular mechanisms and proteins involved in cell resistance to DNA damage are 100 
base excision repair (BER), ataxia-telangiectasia mutated (ATM) and ataxia 101 
telangiectasia and Rad3-related (ATR) (reviewed in [34]). 102 
Studies demonstrated that HCMV upregulates the host BER machinery [35], 103 
activates the DNA damage response [36], and significantly reduces cyclobutane 104 
pyrimidine dimers in UV-exposed viral DNA [37], indicating a viral role in inducing DNA 105 
repair pathways that may limit DNA damage. On the other hand, HCMV was also found 106 
to cause DNA damage. For example, the HCMV protein UL76 was demonstrated to 107 
induce chromosomal aberrations [38], and the virus has been associated with specific 108 
damage at several loci in chromosome 1, 1q21, 1q23 and 1q42 [39, 40].  These 109 
findings lead to the speculation that the virus might either increase or decrease cell 110 
resistance to DNA damaging chemotherapeutic drugs. 111 
To investigate these possibilities, we analyzed infection by low and high 112 
passage strains of HCMV in different GBM cell lines and their response to 113 
chemotherapy treatment in the presence and absence of the virus. 114 
RESULTS 115 
 116 
GBM cell lines are generally susceptible to HCMV infection but not equally 117 
permissive to viral replication 118 
 119 
We and others have demonstrated that HCMV DNA and proteins are present in 120 
GBM tumors [14, 15]. However, few cells in the tumor bulk seem to contain viral DNA, 121 
transcripts and/or proteins [14], indicating that HCMV infection or replication is not 122 
equally efficient in all tumor cells. We therefore sought to investigate viral infection and 123 
replication using GBM cell lines and HCMV strains with different genetic backgrounds. 124 
The GBM cell lines A172, TP365MG and U251MG were exposed to a low 125 
passage (TB40E) and a high passage (AD169) HCMV strain at MOI 3, and the 126 
presence of intracellular pp65 protein, a major component of HCMV particles, was 127 
evaluated at 2 h post infection (hpi) by confocal immunofluorescence microscopy. The 128 
pp65 associated with the input virus was detected in the vast majority (>90%) of cells 129 
in all infections, indicating no significant difference in virus entry among the different 130 
cell lines or HCMV strains (Fig. 1). 131 
To examine the extent and temporal pattern of HCMV protein accumulation 132 
following infection, viral protein markers for the immediate-early (IE1-72kDa), early 133 
(pp52 also known as pUL44) and late (pp28) stages of viral replication were analyzed 134 
at different times post infection by immunofluorescence. Very different patterns of 135 
expression were observed in the three cell lines (Fig. 2 and 3). Controls are shown in 136 
Figures S1 and S2. The IE1-72kDa protein was detectable in only a small subset 137 
(<20%) of A172 cells at 16 hpi, and the proportion of cells staining positive for this 138 
protein further decreased over time (30‒96 hpi). Neither pp52 nor pp28 proteins were 139 
detected at any time point evaluated in this cell line. In contrast, IE1-72kDa was 140 
observed in 40% to >70% of TP365MG and U251MG cells at 16 hpi, and up to almost 141 
100% of these cells stained positive for IE1-72kDa at later times post infection. 142 
However, pp52 and pp28 protein accumulation differed markedly in the two cell lines. 143 
While most of the TP365MG cells had accumulated pp52 and pp28 by 96 hpi, the two 144 
proteins were detectable in only a small proportion of U251MG cells at this time. 145 
Together the results show that all GBM cell lines tested are highly and equally 146 
susceptible to low and high passage strains of HCMV. However, the temporal pattern 147 
of immediate-early, early and late viral protein accumulation varies widely between the 148 
cell lines suggesting major differences in permissivity to HCMV replication determined 149 
by the cellular genetic background. 150 
 151 
HCMV replication reduces the number of viable GBM cells but does not increase 152 
tumor cell resistance to TMZ or BCNU 153 
 154 
Previous studies have shown that HCMV can augment or inhibit cellular DNA 155 
damage responses. Therefore, we aimed to evaluate the effect of HCMV infection on 156 
chemotherapy treatment of GBM cell lines with the DNA damaging drugs TMZ or 157 
BCNU. 158 
Initially, viability of non-infected A172, TP365MG and U251MG cells in the 159 
presence of 25, 50 and 100 µM TMZ or BCNU for 96, 120 and 144 h was assessed by 160 
MTT assay. Compared to controls, both drugs caused a marked decrease of in the 161 
number of viable cells in a concentration-and time-dependent manner in all three cell 162 
lines (Fig. 4). However, the timing and extent by which cell viability was reduced varied 163 
with different combinations of drugs and cell lines. Further analyses were performed 164 
with drug concentrations that decrease cell viability by at least 30%, namely 50 µM 165 
TMZ or BCNU for A172 and TP365MG cells and 75 µM TMZ or 35 µM BCNU for 166 
U251MG cells. 167 
Subsequently, GBM cells were exposed to HCMV AD169 or TB40E at different 168 
MOIs (0.12, 0.6 and 3) or mock infection overnight and treated with TMZ, BCNU or 169 
solvent (DMSO or EtOH, respectively) for 96 h. Infection with either virus strain lead to 170 
a marked decline in the number of TP365MG and U251MG viable cells, even in the 171 
absence of drug. The reduction in the number of viable TP365MG cells was MOI-172 
dependent for both AD169 and TB40E. However, only AD169 but not TB40E reduced 173 
the number of viable U251MG cells in an MOI-dependent fashion. As expected, TMZ 174 
and BCNU reduced cell viability in all cell lines in the absence of virus.  175 
In U251MG cells, high MOI infection with AD169 and treatment with BCNU 176 
appeared to work additively in reducing the number of viable cells. Similar additive 177 
effects were less pronounced or absent upon treating AD169-infected U251MG cells 178 
with TMZ or infecting these cells with TB40E. Likewise, BCNU and TMZ did no exert 179 
significant additive effects when combined with AD169 or TB40E infection of TP365MG 180 
cells, most likely due to the pronounced reduction in the number of viable cells caused 181 
by HCMV alone in this system. Finally, there was no significant impact of HCMV on 182 
A172 cell viability, and no obvious additive effects between the viruses and drugs were 183 
observed in these cells (Fig. 5). 184 
These results show that HCMV infection adversely affects viability of permissive 185 
GBM cells, but does not increase chemoresistance of the cell lines tested. Instead, 186 
HCMV may even increase susceptibility to BCNU under certain conditions. 187 
 188 
Intracellular presence of HCMV is required to reduce GBM cell viability 189 
 190 
It has been demonstrated that HCMV infection leads to the production and 191 
secretion of numerous cytokines some of which may adversely affect cell viability [41]. 192 
For example, the HCMV interleukin 10 homolog (cmvIL10) has been shown to mediate 193 
local tumor immunosuppression and activation of signal transducer and activator of 194 
transcription 3 (STAT3), a transcription factor associated with chemoresistance in 195 
ovarian cancer [42]. Our previous cell viability analyses were performed in de novo 196 
infected cells, suggesting that viral gene expression or replication caused the 197 
substantial reduction in the number of viable cells. However, this approach may mask 198 
possible indirect effects the virus may exert on the viability of uninfected cells by 199 
causing the release of soluble factors. 200 
To test the possibility that soluble factors released from infected cells contribute 201 
to reduction in the number of viable cells even in the absence of infection A172, 202 
TP365MG and U251MG cells were inoculated with supernatants from MRC-5 cells 203 
infected with HCMV AD169 or TB40E for 48 h, and treated with the two 204 
chemotherapeutic drugs for 96 h. Expression of cmvIL10 in infected MRC-5 cells was 205 
confirmed by Western blotting (data not shown). Notably, only A172 cells treated with 206 
supernatants from AD169- or TB40E-infected cells and treated with TMZ exhibited a 207 
significant decrease in number of viable cells. This phenotype was not observed with 208 
any other combination of cells, viruses and drugs (Fig. 6). 209 
These results confirm that reduced number of viable GBM cells caused by 210 
HCMV infection largely depends on the presence of the virus in the affected cells and 211 
likely results from viral gene expression and replication. 212 
 213 
HCMV infection reduces GBM cell proliferation and induces tumor cell death 214 
 215 
To further explore the impact of HCMV on GBM cell viability, we determined the 216 
amount of cell death in U251MG cells by fluorescence-activated cell sorting (FACS). 217 
U251MG cells were infected at MOI 3 overnight, and treated with low concentrations 218 
(25 µM) of TMZ or BCNU for 96 h. U251MG cells were chosen for this experiment due 219 
to the less pronounced decrease in cell viability upon viral infection compared to 220 
TP365MG cells, and the low drug concentration was used to limit cell debris during the 221 
analysis. IE1-72kDa was used as a marker for viral infection. Only a small proportion 222 
(<10%) of cells were positive for both propidium iodide (PI) and IE1-72kDa (Fig. 7a), 223 
suggesting that most of the infected cells were still viable. Further cell death analysis 224 
by trypan blue exclusion assay performed in TP365MG and U251MG cells confirmed 225 
a reduction in infected cell numbers when compared with controls. However, the 226 
percentage of viable cells in this assay proved to be higher than that obtained in the 227 
metabolic assays (Fig. 7b and Fig. 5). 228 
These findings indicate that the reduced number of viable cells observed in 229 
HCMV-infected GBM cell lines is largely due to decreased cell proliferation, and that 230 
cell death makes a minor contribution to the overall effect. 231 
DISCUSSION 232 
 233 
Glioblastoma is a highly heterogeneous tumor, with genetic diversity existing 234 
both among patients and within individual tumors [43]. The intratumoral genetic 235 
heterogeneity can result in many phenotypes including populations of drug resistant 236 
subclones that are the main cause of treatment failure. HCMV is an infectious agent 237 
detected in GBM samples worldwide, although usually only in a subset of tumor cells 238 
[14]. There are also studies that failed to detect HCMV in GBM [44–46]. The causes 239 
underlying the presence or absence of HCMV in GBM cells and the consequences 240 
resulting from infection are not well understood. It has been demonstrated that HCMV 241 
can mediate DNA damage, but the virus can also induce DNA repair pathways [36, 242 
37], phenotypes that could interfere in GBM chemotherapeutic treatment. 243 
Our results demonstrate that three different GBM cell lines (A172, TP365MG 244 
and U251MG) are equally susceptible to HCMV infection. This conclusion is based on 245 
the intracellular presence of the major viral tegument component (pp65) in a similar 246 
number of cells at the beginning of infection. However, the permissivity of the cell lines 247 
to the temporal accumulation of HCMV proteins differs widely, again in a manner 248 
independent of the virus strain. While A172 cells undergo an infection that seems to 249 
be silenced or aborted at the immediate-early stage, TP365MG and U251MG cells are 250 
permissive to viral early and late gene expression. However, infection progresses more 251 
rapidly in TP365MG compared to U251MG cells. High passage (AD169) and low 252 
passage (TB40E) HCMV strains showed very similar phenotypes in terms of both 253 
infectivity and viral protein accumulation in the tested cell lines. These results suggest 254 
that the permissivity of GBM cells to HCMV replication is determined by cellular rather 255 
than viral factors. In fact, the three cell lines under investigation have different 256 
backgrounds with respect to important genes including CDKN2A, PTEN, p16, and p53 257 
[47–50]. Further studies are necessary to investigate the significance of mutations in 258 
these and other genes for permissivity to HCMV gene expression and replication in 259 
both cell lines and tumor tissue. Although we did not perform experiments in tumor 260 
tissue, the cell lines used in this work have been commonly used as experimental 261 
models in GBM research. Our results are compatible with the general view that HCMV 262 
is present in a limited number of cells in GBM tumor samples [14] implying that genetic 263 
differences between cells may result in different outcomes of infection. 264 
Treatment of all three cell lines with TMZ or BCNU causes significant reduction 265 
in the number of viable cells in a dose-and time-dependent manner. In TP365MG cells 266 
both drugs caused a similar decrease in the number of viable cells. In contrast, 267 
U251MG cells treated with BCNU exhibited a decline in the number of viable cells of 268 
almost 100% at 144 h, a phenotype not observed with TMZ. It has been previously 269 
shown that BCNU induces cell death by necrosis and apoptosis in U138MG cells, a 270 
GBM cell line which carries mutant p53 and is therefore more susceptible to toxicity by 271 
BCNU than TMZ [51]. These findings are consistent with our own results, since 272 
U251MG cells carry mutant p53. However, the same phenotype is not observed in 273 
TP365MG cells which also have mutant p53, indicating that drug sensitivity is not 274 
exclusively linked to p53 status [52]. Notably, viral infection alone reduced the number 275 
of viable U251MG and TP365MG cells, which are both permissive to HCMV early and 276 
late gene expression, in a MOI-dependent manner. This phenotype was particularly 277 
pronounced in TP365MG cells, most likely due to their high levels of HCMV gene 278 
expression. No major effects were observed in A172 cells where viral protein 279 
accumulation is limited to immediate-early.  280 
 The concomitant presence of HCMV and TMZ or BCNU caused a further 281 
reduction in the number of viable cells. Interestingly, the reduction in the number of 282 
viable TP365MG cells was MOI-dependent for both AD169 and TB40. However, only 283 
AD169 but not TB40E reduced the number of viable U251MG cells in an MOI-284 
dependent fashion.  This difference could reflect the genetic differences in the virus 285 
strains used in this study, such as the genes from the UL-b' region of the genome, 286 
which has been deleted from AD169 but are present in TB40E [53]. 287 
Overall, our results indicate that HCMV replication occurs differentially in GBM 288 
cell lines depending on their genetic background and that the adverse effects HCMV 289 
confers on GBM cells is likely caused mainly by reduction of cell proliferation, as shown 290 
by FACS and trypan exclusion assay, although cell death also contributes.  291 
The effects HCMV may exert during chemotherapy treatment of GBM was 292 
previously investigated in several cell types including astrocytoma cells, breast cancer 293 
cells, neuroblastoma cells, peripheral blood lymphocytes and smooth muscle cells, but 294 
the results are controversial. HCMV-infected astrocytoma cells showed a decrease in 295 
apoptosis when treated with cisplatin, a phenotype also observed in etoposide-treated 296 
MDA-MB-231 breast cancer cells [54–57]. Likewise, UKF-NB-2A-AD169 cells, a 297 
neuroblastoma cell line persistently infected with HCMV, were more resistant to 298 
cisplatin-induced cell death [58] . Conversely, treatment with ganciclovir re-established 299 
sensitivity to chemotherapy in neuroblastoma and astrocytoma cell lines persistently 300 
infected with HCMV [56, 58]. HCMV has also been reported to increase resistance of 301 
glioma cancer stem cells to TMZ [59]. On the other hand, HCMV has been shown to 302 
increase genetic damage induced by bleomycin in peripheral blood lymphocytes [60, 303 
61]. Interestingly, HCMV IE1-72kDa seems to stimulate while IE2-86kDa may 304 
suppress doxorubicin-induced apoptosis in smooth muscle cells [62]. We demonstrate 305 
here that HCMV does not increase resistance in three GBM cell lines. Instead, the virus 306 
causes a reduction in TP365MG and U251MG cell proliferation or survival both in the 307 
absence and presence of the tested drugs. These findings highlight that HCMV not 308 
only exhibits tumor promoting potential but may also exert adverse oncomodulatory 309 
effects depending on tumor cell permissivity to viral replication. In tumor cells 310 
permissive to viral early and late gene expression, the virus may be oncostatic or 311 
oncolytic while the tumor promoting activities linked to viral immediate-early proteins 312 
may predominate in cells with restricted viral replication. 313 
Many studies have been conducted to understand the relationship between 314 
HCMV and GBM, but we are still far from understanding the role the virus may have in 315 
tumor pathogenesis. Our results indicate that HCMV does not increase GBM cell 316 
resistance to TMZ and BCNU in vitro. However, further studies need to be done to 317 
examine whether the virus behaves similarly in other tumor cell lines and in in vivo. 318 
METHODS 319 
 320 
Cell culture and virus production 321 
 322 
Human glioblastoma cell lines A172, TP365MG and U251MG were provided by 323 
Dr. Markus Riemenschneider, University of Regensburg. MRC-5 human embryonic 324 
lung fibroblast cells were obtained from the American Type Culture Collection. Cells 325 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal 326 
bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Thermo Fisher 327 
Scientific) at 37˚C in a humidified atmosphere with 5% CO2. 328 
HCMV BADinUL99GFP [63] was produced by electroporation, and AD169 and 329 
TB40E were produced by nucleofection of MRC-5 cells with the corresponding 330 
bacterial artificial chromosome clones (provided by Dr. Thomas Shenk, Princeton 331 
University). Cell supernatants containing virus were collected after complete cell lysis 332 
and cleared of cell debris by low-speed centrifugation. Cell-free virus stocks were 333 
stored at -80˚C. For virus titration, serial dilutions of stocks were plated on MRC-5 cells. 334 
At 24 hpi, cells were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-335 
100, and blocked with 3% BSA. Cells were labeled using a hybridoma supernatant of 336 
a primary mouse antibody to IE1 (1B12) [64] diluted 1:5, and a secondary goat anti-337 
mouse antibody conjugated to Alexa Fluor 594 (Abcam, ab150116) diluted 1:1000. 338 
Nuclei were stained with Hoechst 33342 (Abcam, ab145597). Virus titers were 339 
expressed as plaque forming units per ml. 340 
 341 
Infection and viral protein detection 342 
 343 
To determine viral protein levels during a time course, A172, TP365MG and 344 
U251MG cells were plated in low serum (1%) media at a density of 100.000 cells on 345 
glass coverslips in 24-well plates and infected with HCMV AD169 or TB40E at MOI 3 346 
overnight. After that, the inoculum was removed and replaced by fresh medium. Cells 347 
were maintained until 24, 48, 72, or 96 hpi (U251MG were also infected for 120 h) and 348 
subjected to standard or confocal epifluorescence microscopy. Briefly, cells were 349 
washed in PBS with 0.05% Tween 20 (PBS-T) and fixed with iced methanol for 15 min 350 
at -20ºC. Methanol was then removed, coverslips dried, and cells blocked with 2% BSA 351 
in PBS-T for 1 h. Cells were incubated with primary antibodies mouse anti-pp65 (1:10), 352 
mouse anti-IE1-72kDa (1:200), mouse anti-pp52 (1:100) or mouse-anti pp28 (1:10) 353 
(provided by Dr. Thomas Shenk, Princeton University) for 1 h, washed and incubated 354 
with a secondary goat anti-mouse antibody conjugated to Alexa 594 (1:1000) (Abcam, 355 
ab150116). Controls included mock infected cells with HCMV specific primary 356 
antibodies and secondary antibody, mock infected cells with secondary antibody only, 357 
HCMV infected cells with secondary antibody only (Fig. S1). In addition 358 
immunofluorescence experiments were performed in mock and HCMV infected cells 359 
using a mouse monoclonal antibody against the VP1 protein of JC polyomavirus 360 
(Abcam, ab34756) and the secondary anti-mouse conjugate from the above 361 
experiments (Fig. S2).  362 
Coverslips were mounted with 4',6-diamidino-2-phenylindole (DAPI). For 363 
standard fluorescence microscopy, cells were observed using an EVOS FL Cell 364 
Imaging System (Thermo Fisher Scientific) and quantified with ImageJ software using 365 
the following formula: % infected cells = number of infected cells (red) / total number 366 
of cells (blue) × 100%. For confocal fluorescence microscopy, a series of z-images 367 
were recorded using a Leica TCS SP5 confocal microscope (Leica Microsystems).  368 
 369 
Cell viability and cell death assays 370 
 371 
TMZ (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-372 
carboxamide) and BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) were purchased from 373 
Sigma-Aldrich, and stock solutions (100 mM) were prepared by dissolving the drugs in 374 
dimethyl sulfoxide (DMSO) or ethanol (EtOH), respectively. Solutions were aliquoted 375 
and stored at -20°C. For cytotoxicity analysis, A172, TP365MG and U251MG cells 376 
(10.000 cells/well) were incubated in triplicates overnight in 24-well plates. On the next 377 
day, the culture supernatants were replaced with fresh media containing 25, 50 or 100 378 
μM TMZ or BCNU, and cells were incubated for 96, 120 and 144 h. 379 
To determine the effects of HCMV during drug treatment, A172, TP365MG and 380 
U251MG cells were plated in medium with low serum (10.000 cells/well in 24-well 381 
plates), infected at MOI 3 overnight with AD169 or TB40E, and treated with 382 
chemotherapeutic drugs. A172 and TP365MG cell lines were treated with 50 μM BCNU 383 
or TMZ and U251MG cells were treated with 25 μM BCNU or 75 μM TMZ. In all cases, 384 
cells were incubated for 96 h and cell viability was analyzed by MTT (3-(4,5-385 
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) or Alamar Blue assays (Thermo 386 
Fisher Scientific). The MTT assay was performed as previously reported[65, 66]. 387 
Briefly, after incubation with drugs the medium was removed, cells were washed twice 388 
with PBS, and 200 µL of a 0.5 mg/mL MTT solution in serum-free medium was added 389 
to each well. The cells were incubated for 4 h at 37°C, medium was removed, and 390 
formazan crystals were solubilized in 300 μl DMSO. The plate was shaken for 15 min 391 
and absorbance was measured at 570 nm. For the Alamar Blue assay, 100 µL reagent 392 
was added directly to the culture media and incubated for 3 h. Fluorescence was 393 
measured at 530 nm excitation and 560 nm emission. In both assays results were 394 
compared to controls considered 100% viable, where cells were seeded and cultivated 395 
as described but not exposed to drugs and/or virus. DMSO or EtOH were used as 396 
solvent controls for TMZ and BCNU, respectively, at concentrations below 0.1% 397 
(concentration non-toxic to the cells). For trypan blue staining, A172, TP365MG and 398 
U251MG cells were plated and treated as in the cell viability assays. After treatment, 399 
cells were trypsinized, and the cell suspension mixed with 0.4% trypan blue solution at 400 
a 1:1 ratio. Live and dead cells were counted using a Neubauer chamber. The 401 
percentage of living cells was measured using the following formula: % live cells = 402 
number of live cells / (number of live cells + number of dead cells) × 100%. 403 
To determine the effects of the HCMV secretome during drug treatment, MRC-404 
5 cells were infected with AD169 or TB40E at low MOI for 48 h. Cell supernatants were 405 
centrifuged and filtrated through 0.4 µm filters. A172, TP365MG and U251MG cells 406 
were plated overnight (10.000 cells/well), inoculated with 200 μl supernatant overnight, 407 
and treated with chemotherapeutic drugs as described above. After 96 h, cell viability 408 
was analyzed by MTT assay. 409 
 410 
Flow cytometry 411 
 412 
U251MG cells (10.000 cells/well) were infected with HCMV BADinUL99GFP or 413 
mock-infected and treated with 25 μM TMZ or BCNU, incubated with PI for 15 min, 414 
trypsinized, and collected. After centrifugation and washing, cells were permeabilized 415 
with 0.1% Triton X-100, blocked with 3% BSA solution, and incubated overnight with 416 
anti-IE1 antibody (1:5) followed by goat anti-mouse Alexa 488 antibody (Abcam, 417 
ab150113) (1:250) for 30 min. The cell pellet was re-suspended in PBS, and 10,000 418 
events were analyzed in a BD FACSCalibur flow cytometer. 419 
 420 
Statistical analysis 421 
 422 
All experiments were performed at least twice (biological duplicates) in technical 423 
triplicates. Statistical analysis was performed using two-way ANOVA (GraphPad 424 
Prism). P<0.05 was considered statistically significant. 425 
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 629 
FIGURE LEGENDS 630 
 631 
Fig. 1. Detection of viral pp65 protein in HCMV-infected GBM cells. A172, 632 
TP365MG and U251MG cells were infected with HCMV AD169 or TB40E at MOI 3 for 633 
2 h. Confocal immunofluorescence microscopy was performed, and a series of z-634 
images were recorded.  The HCMV pp65 protein is shown in green, cell nuclei are 635 
shown in blue, and merge. Images were taken at magnification objective of 63x.  636 
 637 
Fig. 2. Expression of viral IE1-72kDa, pp52 and pp28 proteins in HCMV-infected 638 
GBM cells. A172, TP365MG and U251MG cells were infected with HCMV AD169 or 639 
TB40E at MOI 3 for 16, 48 or 96 h and analyzed by immunofluorescence microscopy. 640 
HCMV proteins are shown in red, cell nuclei are shown in blue, and merge images is 641 
shown as well. Images were taken at magnification objective of 20x. 642 
 643 
Fig. 3. Quantification of viral IE1-72kDa, pp52 and pp28 protein accumulation in 644 
HCMV-infected GBM cells. Immunofluorescence microscopy for HCMV immediately 645 
early (IE1-72kDa), early (pp52) and late (pp28) proteins was performed at different 646 
times post infection in A172, TP365MG and U251MG cells. Results are expressed as 647 
a percentage of infected cells divided by the number of total cells. At least 100 cells 648 
were counted for each immunofluorescence sample using ImageJ. 649 
 650 
Fig. 4. Cell viability of GBM cells after treatment with TMZ and BCNU. The number 651 
of A172, TP365MG and U251MG viable cells was assessed by MTT assay after 652 
treatment with 25, 50 or 100 µM TMZ or BCNU for 96, 120 and 144 h. Data represent 653 
the mean (± standard deviation, SD) of three independent experiments done in 654 
triplicate, p<0.05. 655 
 656 
Fig. 5. Cell viability of GBM cells after HCMV infection at different MOIs and 657 
treatment with TMZ and BCNU. Cell viability was assessed by MTT assay for A172 658 
cells and by Alamar Blue assay for TP365MG and U251MG cells after overnight 659 
infection with HCMV AD169 or TB40E at the indicated MOIs and treatment with 660 
chemotherapeutic drugs. A172 and TP365MG cells were treated with 50 µM TMZ or 661 
BCNU for 96 h, and U251MG cells were treated with 75 µM TMZ and 35 µM BCNU for 662 
96 h. Data represent the mean (± standard deviation, SD) of three independent 663 
experiments, * p<0.05, ** p<0.0036, *** p<0.0009; **** p<0.0001. 664 
 665 
Fig. 6. Cell viability of GBM cells after incubation with supernatants from HCMV-666 
infected cells and treatment with TMZ and BCNU. A172, TP365MG and U251MG 667 
cell viability was assessed by MTT assay after overnight incubation with supernatants 668 
of AD169- or TB40E-infected MRC-5 cells for 48 h and treatment with 669 
chemotherapeutic drugs for 96 h. A172 and TP365MG cells were treated with 50 µM 670 
TMZ or BCNU, and U251MG cells were treated with 75 µM TMZ or 35 µM BCNU. Data 671 
represent the mean (± standard deviation, SD) of three independent experiments, ** 672 
p< 0.0098. 673 
 674 
Fig 7. Cell death analysis of HCMV-infected GBM cells. (A) FACS analysis of 675 
U251MG cells infected overnight with BADinUL99GFP at MOI 3 (HCMV) or mock-676 
infected after treatment with 25 μM TMZ or BCNU for 96 h. A monoclonal antibody 677 
against HCMV IE1-72kDa was used as a marker for infection and propidium iodide (PI) 678 
as a marker for cell death. (B) For trypan blue exclusion assay A172, TP365MG and 679 
U251MG cells were infected overnight at MOI 3 with HCMV AD169 or TB40E and 680 
treated with chemotherapeutic drugs for 96 h. A172 and TP365MG cells were treated 681 
with 50 µM TMZ or BCNU, and U251MG cells were treated with 75 µM TMZ or 35 µM 682 
BCNU. After treatment, cells were trypsinized and the cell suspension mixed with 0.4% 683 
trypan blue solution at a 1:1 ratio. Living and dead cells were counted using a 684 
Neubauer chamber. Data represent the mean (± standard deviation, SD) of three 685 
independent experiments, * p<0.05, ** p<0.0036, ***p<0.0009. 686 
 687 
 688 
Fig. S1. Control experiments for the analysis of viral protein expression.  689 
Immunofluorescence microscopy in mock-infected cells with HCMV-specific primary 690 
antibodies for HCMV proteins and secondary antibody; mock-infected cells with 691 
secondary antibody only and HCMV-infected cells with secondary antibody only. 692 
HCMV proteins are shown in red, cell nuclei are shown in blue. Images were taken at 693 
magnification objective of 20x. 694 
 695 
Fig. S2. Control experiments for the analysis of HCMV protein expression. 696 
Immunofluorescence microscopy in mock-infected and HCMV infected cells with a 697 
mouse monoclonal antibody against the VP1 protein of JC polyomavirus and the 698 
secondary. IE1 staining in HCMV infected cells is shown as positive control. Positive 699 
control for HCMV infection. Viral proteins are shown in red, cell nuclei are shown in 700 
blue. Images were taken at magnification objective of 20x. 701 
 702 
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Fig. S1. Control experiments for the analysis of viral protein expression.  2 
Immunofluorescence microscopy in mock-infected cells with HCMV-specific primary 3 
antibodies for HCMV proteins and secondary antibody; mock-infected cells with 4 
secondary antibody only and HCMV-infected cells with secondary antibody only. 5 
HCMV proteins are shown in red, cell nuclei are shown in blue. Images were taken at 6 
magnification objective of 20x. 7 
 8 
 9 
Fig. S2. Control experiments for the analysis of HCMV protein expression. 10 
Immunofluorescence microscopy in mock-infected and HCMV infected cells with a 11 
mouse monoclonal antibody against the VP1 protein of JC polyomavirus and the 12 
secondary. IE1 staining in HCMV infected cells is shown as positive control. Positive 13 
control for HCMV infection. Viral proteins are shown in red, cell nuclei are shown in 14 
blue. Images were taken at magnification objective of 20x. 15 
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